{
    "body": "Is recommended the use of perioperative treatment with thyroid hormone therapy in patients undergoing coronary artery bypass grafting?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7477166", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20668034", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14500064", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12213743", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12643405", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8633935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12079930", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12800543", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1859661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10343261", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18290900", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16719939", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3872103", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8389710", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8594265"
    ], 
    "ideal_answer": [
        "Currently there is no substantial evidence to justify routine use of thyroid hormones in patients undergoing coronary artery bypass grafting."
    ], 
    "exact_answer": "no", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003324", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D047549", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003331", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001026"
    ], 
    "type": "yesno", 
    "id": "53267871d6d3ac6a3400000a", 
    "snippets": [
        {
            "offsetInBeginSection": 1517, 
            "offsetInEndSection": 1615, 
            "text": "Short duration postoperative iv T(3) therapy increases cardiac index and does not alter mortality.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20668034", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 496, 
            "offsetInEndSection": 835, 
            "text": "We conclude that although widespread interest has been shown on the use of thyroid hormones in the perioperative period, and the effect of cardiopulmonary bypass on thyroid hormone metabolism widely studied, there is no substantial evidence to justify routine use of thyroid hormones in patients undergoing coronary artery bypass grafting.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18290900", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1104, 
            "offsetInEndSection": 1417, 
            "text": "There is no clear evidence at this point to support thyroid hormone replacement in the latter patients, and it may be potentially harmful. Rather, we hold that T3 treatment of various surgical and other patients with nonthyroidal illness should be deferred until proof of its therapeutic efficacy is demonstrated.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12800543", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1053, 
            "offsetInEndSection": 1282, 
            "text": "Perioperative administration of triiodothyronine increased cardiac output slightly and decreased systemic vascular resistance, but it had no effect on operative outcome. Routine use after coronary surgery is thus not recommended.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213743", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1625, 
            "offsetInEndSection": 1835, 
            "text": "Although mild effects on myocardial performance may exist, we cannot recommend at this time the routine use of intravenous T(3) as an inotropic agent in patients undergoing coronary artery bypass graft surgery.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8594265", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1978, 
            "offsetInEndSection": 2225, 
            "text": "Raising serum triiodothyronine concentrations in patients undergoing coronary-artery bypass surgery increases cardiac output and lowers systemic vascular resistance, but does not change outcome or alter the need for standard postoperative therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7477166", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1367, 
            "offsetInEndSection": 1483, 
            "text": "Thus, there seems to be no sound justification for a routine use of T3 in patients undergoing open-heart procedures.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8389710", 
            "endSection": "abstract"
        }
    ]
}